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Abstract
Background: The balancing functions of pro/anti-inflammatory mediators of the complex innate responses have
been investigated in a variety of experimental inflammatory settings. Annexin-A1 (AnxA1) is one mediator of
endogenous anti-inflammation, affording regulation of leukocyte trafficking and activation in many contexts, yet its
role in lung pathologies has been scarcely investigated, despite being highly expressed in lung cells. Here we have
applied the bleomycin lung fibrosis model to AnxA1 null mice over a 21-day time-course, to monitor potential
impact of this mediator on the control of the inflammatory and fibrotic phases.
Results: Analyses in wild-type mice revealed strict spatial and temporal regulation of the Anxa1 gene, e.g. up-
regulation in epithelial cells and infiltrated granulocytes at day 7, followed by augmented protein levels in alveolar
macrophages by day 21. Absence of AnxA1 caused increases in: i) the degree of inflammation at day 7; and ii)
indexes of fibrosis (assessed by deposition of hydroxyproline in the lung) at day 7 and 21. These alterations in
AnxA1 null mice were paralleled by augmented TGF-b1, IFN-g and TNF-a generation compared to wild-type mice.
Finally, treatment of wild type animals with an AnxA1 peptido-mimetic, given prophylactically (from day 0 to 21) or
therapeutically (from day 14 onward), ameliorated both signs of inflammation and fibrosis.
Conclusion: Collectively these data reveal a pathophysiological relevance for endogenous AnxA1 in lung
inflammation and, more importantly, fibrosis, and may open new insights for the pharmacological treatment of
lung fibrosis.
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Background
Pulmonary fibrosis, a severe pathological outcome asso-
ciated with several lung diseases, can be commonly
reproduced by intratracheal instillation of bleomycin, a
cytotoxic chemotherapeutic agent. The tissue remodeling
that ensues is characterized by severe inflammation (evi-
dent from edema and leukocyte migration) and a delayed
phase with fibroblast proliferation and excess matrix
deposition [1]. The pathological events leading to pul-
monary fibrosis have been attributed to an overproduc-
tion of interstitial collagens by cytokine-activated
fibroblasts [2]; moreover, though a variety of cytokines
have been implicated in fibroblast activation, a para-
mount causative role for transforming growth factor
(TGF)-b1 has emerged. This cytokine activates fibroblast
differentiation into myofibroblasts [3] and stimulates
extracellular matrix (ECM) production [4]. However,
besides its pro-fibrotic properties, TGF-b1 exerts a num-
ber of other homeostatic functions in immune and can-
cer biology [5], so that inhibition of TGF-b1 would
provoke a series of adverse effects, making it not that
valuable as a therapeutic approach. Other therapeutic
interventions include anti-inflammatory drugs (e.g. glu-
cocorticoids as prednisone) that are effective to relieve
disease without halting fibrosis progression. Anti-fibrotic
drugs do not improve lung function or life expectancy
and their use may also be associated with harmful side
effects [6]. Nonetheless, our knowledge on the underlying
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mechanisms of pulmonary fibrosis is increased, and this
might help for the identification of targets amenable for
the development of novel therapies [7].
There is great interest on biochemical pathways cen-
tered on endogenous inhibitors endowed with counter-
regulatory and protective functions [8]. Most of these
studies have focused on acute inflammation, elucidating
endogenous anti-inflammatory pathways that operate in
parallel, and sometimes in a time-delayed fashion, to the
more widely studied pro-inflammatory mediators, to
ensure rapid resolution of the host response with return
to tissue homeostasis [9]. One line of research has
focused on the glucocorticoid-regulated protein annexin
A1 (AnxA1; 346 amino acids long; 37 kDa protein), a
potent modulator of leukocyte trafficking/transmigration
in acute and chronic inflammation [10,11], with a parti-
cular ability to inhibit the leukocyte/endothelium inter-
action in the microvasculature [12]. Characterization of
an AnxA1 null mouse colony has revealed, upon stimu-
lation, a dysregulation of pathophysiological mechan-
isms, with an exacerbation of acute and chronic
experimental inflammatory responses [12-15].
The AnxA1 protein is highly expressed in the airways,
both in human/animal alveolar macrophages and epithelial
cells [16-18], a finding explained by constitutive gene pro-
moter activity in bronchial epithelium and lung endothe-
lial cells [12,15]. The AnxA1 anti-inflammatory effects can
be replicated by a shorter peptide spanning the first 25
amino acids, termed peptide Ac2-26. Both AnxA1 and its
N-terminal derived peptides exert potent regulation of the
inflammatory reaction by activating its receptor, the for-
myl-peptide receptor (FPR) [19-21], with consequent inhi-
bition of white blood cell trafficking and promotion of
efferocytosis [22,23]. Of interest in the context of lung
inflammation, down-regulation of endogenous AnxA1
expression has been noted in the bronchoalveolar lavage
(BAL) fluid of cystic fibrosis patients [24]. More recently,
blockade of the transmembrane conductance regulator
protein (CFTR) led to the release of AnxA1 from human
and mouse neutrophils, a finding associated with an
altered acute inflammatory reaction [25].
Against this background, the present study was under-
taken to compare cellular, tissue and macroscopic
alterations observed in the model of bleomycin-induced
lung fibrosis in wild type and AnxA1 null mice. More-
over, the pattern of expression of the endogenous pro-
tein and gene promoter activity were monitored, and
the pharmacological potential of AnxA1 peptido-
mimetic was assessed.
Methods
Animals
Male C57bl/6 wild type and AnxA1 null mice [14,15]
(20-25 g of body weight), maintained on a standard
chow pellet diet with tap water ad libitum, were used
for all experiments. Animals were housed at a density of
five animals per cage in a room with controlled lighting
(lights on from 8:00 a.m. to 8:00 p.m.) in which the tem-
perature was maintained at 21-23°C. Animal work was
performed according to UK Home Office regulations
(Guidance on the Operation of Animals, Scientific Pro-
cedures Act 1986), Committee of Ethics in Animal
Research, FAMERP, SP, Brazil (Protocol n°042407) and
along the directives of the European Union.
Murine Model of Lung Fibrosis
Pulmonary fibrosis was induced by intratracheal (i.t.)
administration of bleomycin (Blenoxane, Mead Johnson,
Princeton, NJ) suspended in sterile phosphate-buffered
saline (PBS) at 0.15 U/Kg. Control mice received saline
vehicle only (N = 5 per group). At different time post
intratracheal injection (day 0, 7 and 21) mice were
anesthetized with ketamine (Dopalen, Vetbrands, Brazil,
60%) and xylazine (Anasedan, Vetbrands, Brazil, 40%)
solution (60 μL in total) for blood and BAL fluid collec-
tion. In some cases, animals were perfused with 20 mL
of PBS to remove blood contents from tissues, and lung
were collected and processed as described below. Ani-
mal survival was monitored daily up to 21 days post-
bleomycin. In case of death, the experiments were
repeated to achieve the minimal number of 5 animals
per group.
In some cases, mice were treated daily with 1 mg/kg
intraperitoneally (i.p.) of peptide Ac2-26 (Ac-AMV-
SEFLKQAWFIENEEQEYVQTVK; obtained from Tocris,
Huissen, The Netherlands) starting immediately after
the first dose of bleomycin (bleo+pep; N = 5). Another
group of bleomycin-treated mice received the same dose
and route of peptide Ac2-26 from day 14 to day 21
post-bleomycin (bleo+pep 14-21 d; N = 5). Control
mice were treated daily with Ac2-26 (i.p.), but were i.t.
treated with saline only instead of bleomycin. In all
cases, animals were sacrificed at day 21 for lung histol-
ogy and immunohistochemistry, and Western blotting
analyses.
Histopathological analyses
Wild type and AnxA1 null lungs were excised, fixed in
4% paraformaldehyde, 0.1 M sodium phosphate buffer
(pH 7.4) for 2 h at 4°C; then, they were fragmented,
washed, dehydrated in ethanol, clarified in xylene and
embedded in paraplast™ (Sigma, USA). Histological sec-
tions were cut (Leica RM2265, Leica, GR), mounted on
slides, and stained with Masson’s Trichrome. Quantifica-
tion of leukocyte numbers in tissue samples was per-
formed by the point-counting technique [26] with a
high-power objective (×40) and measuring the area of
analysis with the software Axiovision (Zeiss, GR). Data
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was reported as cells/mm2 (analyzing at least 10 distinct
histological sections per mouse).
Whole Lung Homogenates and Collagen Assays
Total lung hydroxyproline contents were determined
using a well-accepted assay [27]. Briefly, samples of lung
homogenate (500 μL) were added to 1 mL of 6 N
hydrochloric acid for 8 h at 120°C. To a 5 μL sample of
the digested lung, 5 μl of citrate/acetate buffer (5% citric
acid, 7.2% sodium acetate, 3.4% sodium hydroxide, and
1.2% glacial acetic acid, pH 6.0) and 100 μL of chlora-
mine-T solution (282 mg of chloramine-T, 2 ml of N-
propanol, 2 ml of distilled water, and 16 mL of citrate/
acetate buffer) were added. The resulting samples were
then incubated at room temperature for 20 min before
addition of 100 μl of Ehrlich’s solution (Aldrich, Mil-
waukee, WI), 9.3 mL of N-propanol, and 3.9 mL of 70%
perchloric acid. After a further incubation at 65°C sam-
ples for 15 min, samples were read at 550 nm in a
DU640 spectrophotometer (Beckman, Fullerton, CA);
hydroxyproline concentrations were then calculated
from standard curve (0-100 μg/mL hydroxyproline).
Cellular analysis of blood and BAL fluids
Aliquots of blood (20 μL) obtained from the abdominal
artery were diluted 1:10 in Turk’s solution (0.1% crys-
tal violet in 3% acetic acid) for cell quantification.
After semi-excision of the trachea, a plastic cannula
was inserted and airspaces were washed with 0.5 mL
of 0.9% sodium chloride containing 2.6 mM EDTA
with a 1 mL syringe. This operation was repeated
twice. BAL was centrifuged (600 g for 10 min, 4°C)
and the cell-free supernatants were frozen at -80°C for
subsequent cytokine analysis. Cell pellets were re-sus-
pended and an aliquot (190 μL) was diluted 20:1 in
Turk’s solution (3% crystal violet in 20% acetic acid)
for cell quantification.
In both cases, total and differential counting was
obtained with a Neubauer chamber using a ×40 objec-
tive in the light microscope Axioskop II mot plus (Zeiss,
GR). BAL cells were distinguished in polymorphonuclear
(PMN), mononuclear phagocytic cells (monocyte/macro-
phages - MPC) and lymphocytes (LY), whereas blood
cells were divided into PMN, peripheral blood mono-
cytes (PBMC) and LY.
Cytokine levels
Aliquots of blood and BAL fluids were centrifuged at
4000 and 600 g for 10 min, respectively. Concentrations
of tumor necrosis factor (TNF)-a, transforming growing
factor (TGF)-b and interferon (IFN)-g were measured
using specific enzyme-linked immunosorbent assay kits
purchased from R&D System (Abingdon, UK).
Immunohistochemistry
AnxA1 protein expression in tissue cells was determined
by immunohistochemistry, as reported [13]. Briefly, wild
type lung samples were fixed in 4% paraformaldehyde
(in 0.1 M sodium phosphate buffer, 2 h at 4°C, pH 7.4)
and embedded in LR Gold resin (London Resin, UK).
Histological sections (1 μm thick) were blocked with
10% albumin bovine in PBS (PBSA), and a polyclonal
rabbit anti-AnxA1 antibody (Zymed Laboratories) added
(1:200 in 1% PBSA) overnight at 4°C. As negative con-
trol of the reaction, some histological sections of wild
type lungs were incubated with non-immune rabbit
serum (1:200 working dilution; Sigma-Aldrich) instead
of the primary antibody. A goat anti-rabbit IgG (Fc frag-
ment-specific) antibody conjugated to 5 nm colloidal
gold (1:100; British BioCell International) was then
added. Silver enhancing solution (British BioCell Inter-
national) was used to augment gold particle staining and
histological sections were counterstained with haema-
toxylin. Analysis of AnxA1 expression was conducted
with an Axioskop II microscope (Zeiss, Germany). The
stained area was analyzed densitometricaly with the
Software Axiovision™ (Zeiss) to determine the values of
AnxA1 in the cell. The generate values varied from 0 to
255 arbitrary units.
Anxa1 gene expression by LacZ analysis
Spatial and temporal activation of Anxa1 gene promoter
in lung was monitored with histochemical X-Gal stain-
ing, as reported [12], monitoring Prussian blue precipi-
tation as a marker of LacZ gene activity [14,15]. Briefly,
tissues were fixed in 4% paraformaldehyde, 0.1 M
sodium phosphate buffer, pH 7.4, for 2 h at 4°C, and
washed in rinse buffer (0.1 M phosphate buffer pH 8, 2
mM magnesium chloride, 0.1% Triton X-100). Samples
were stained overnight at 37°C with 5 mM potassium
ferricyanide and 5 mM potassium ferrocyanide in rinse
buffer containing 1 mg/mL 5-Bromo-4-chloro-3-indolyl
b-D-galactopyranoside and 4% dimethylformamide.
Samples were then embedded in LR Gold™ resin for
subsequent microscopy analysis. As a negative control
for the reaction, wild type lungs were incubated with X-
Gal staining. Densitometric analysis for X-Gal staining
was performed densitometricaly with the Software Axio-
vision™ (Zeiss) in lung leukocytes and epithelial cells.
The values generated varied from 0 to 255 arbitrary
units.
Western blotting
Lung from control or experimental groups of wild type
mice were homogenized in EDTA free protease inhibitor
(Roche, UK). Protein concentrations were determined by
the Bradford assay (Sigma), mixed 1:1 with Laemmli
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sample buffer [28], and equal protein amounts (30 μg)
electrophoresed in a 10% polyacrylamide gel in running
buffer (0.3% Tris base, 1.44% glycine, 0.1% SDS in dis-
tilled water) followed by transfer of proteins onto
Hybond-C extra nitrocellulose membranes in transfer
buffer (0.3% Tris base, 1.44% glycine, 20% methanol in
distilled water). After membrane blocking with 5% non-
fat milk solution in TBS containing 0.1% Tween 20,
AnxA1 immunoreactivity was assessed using specific
antibody to detect both cleaved (33 kDa) and intact pro-
tein (37 kDa) (1:1000; Invitrogen, USA). The signal was
amplified with HRP-linked anti-mouse secondary anti-
body (1:2000; Amersham Biosciences, USA) and visua-
lized by ECL (Western blotting detection reagent;
Amersham Biosciences, USA).
Data handing and statistical analysis
In all cases data are reported as mean ± SEM of five
mice per group. Statistical differences between groups
were determined by ANOVA followed, if significant, by
the Bonferroni test. In all cases, a probability value
<0.05 was taken as significant. The survival rate was
analyzed using Kaplan-Meier cumulative plots, and
comparisons between groups were performed using a
log-rank test.
Results
Analysis of AnxA1 protein expression and gene promoter
activity in lung fibrosis
We began this study by monitoring AnxA1 protein
expression in wild type and gene promoter activity in
AnxA1 null mice, both in bronchiolar epithelial cells,
circulating and migrated leukocytes. Table 1 and 2
reports the cumulative data obtained from these densi-
tometric analyses.
As predicted [12], immunohistochemistry revealed
intracellular localization for AnxA1 associated to gold
particles in bronchiole epithelial cells (Figure 1A),
mononuclear phagocytic cell (MPC) and circulating
polymorphonuclear (PMN) (Figure 1B). All cells were
positive for AnxA1 under basal conditions (Table 1). At
day 7 post-bleomycin, an increment of AnxA1 expres-
sion was observed in the bronchiolar epithelium (Figure
1C), PMN and MPC of wild type mice (Figure 1D, with
quantitative data shown in Table 1); this cellular
response was no longer evident at day 21 (Figure 1E
and 1F, Table 1). No immunogold staining could be
detected in absence of the primary antibody (Figure 1G
and 1H), confirming the specificity of the AnxA1
staining.
In lungs taken from sham mice (day 0), basal Anxa1
gene promoter activity could be detected in the bronch-
iolar epithelium (Figure 1I), PMN and MPC (Figure 1J).
This colorimetric reaction was markedly augmented at
day 7 (Figure 1K and L) and day 21 (Figure 1M and 1N)
post-bleomycin, with the epithelium and MPC resulting
strongly positive at the later time-point. Table 2 reports
these data in quantitative fashion. As a control for these
data, performing the X-Gal staining protocols on lungs
taken from wild type mice did not yield any coloration
(Figure 1O and 1P).
Lack of AnxA1 exacerbates inflammatory cell activation in
lung fibrosis
The early response to bleomycin-induced fibrosis is
characterized by a dramatic increase in inflammatory
cell recruitment that precedes fibrotic tissue formation
[7]. Bleomycin administration induced marked leukocyte
influx in wild type mice with no influx of blood cells
being found in untreated mice (Figure 2). Quantitative
analysis of several histological lung sections of AnxA1
null and wild type mice revealed rapid and intense leu-
kocyte migration not only in peribronchial and perivas-
cular areas but also in the interstitial space, occurring
both at day 7 and 21 post-bleomycin (Figure 2). At day
7, mice deficient in AnxA1 displayed a higher degree of
PMN and peripheral blood monocytes (PBMC) adhesion
to lung microvessels (Figure 2).
Table 1 Annexin-A1 protein expression in wild type mouse lung tissue and leukocytes during the process of fibrosis
induced by bleomycin
Wild type Epithelial cells PMN MPC
Intra-vascular Trans-migrated Intra-alveolar Intra-vascular Tissue Intra-alveolar
Sham 45 ± 2 101 ± 7 62 ± 2 80 ± 8 41 ± 3 43 ± 4 72 ± 4
Bleo 7d 66 ± 3 * 63 ± 3 * 83 ± 2 * 82 ± 7 63 ± 2 * 72 ± 4 * 74 ± 5
Bleo 7d + Ac2-26 70 ± 5 * 62 ± 2 * 62 ± 3 # 73 ± 8 45 ± 3 # 74 ± 5 * 73 ± 4
Bleo 21d 48 ± 2 64 ± 3 * 70 ± 4 70 ± 7 42 ± 1 44 ± 4 43 ± 4 *
Bleo 21d + Ac2-26 daily 60 ± 3 *# 110 ± 9 # 86 ± 5 * 79 ± 8 55 ± 3 44 ± 3 104 ± 6 #
Bleo 21d + Ac2-26 14-21d 70 ± 4 *# 70 ± 3 * 91 ± 7 *# 81 ± 7 45 ± 4 50 ± 2 55 ± 1
AnxA1 protein expression was analyzed, as described in Material and Methods, in wild type mice lung at 0, 7 and 21 days post-bleomycin i.t. administration. Also
a group of mice were daily i.p. treated or post-treated with the peptide Ac2-26 as described in Material and Methods section. Values (densitometric units) are
mean ± SEM of 10 histological tissue sections analyzed from five mice per group. * P < 0.05 versus sham group values. # P < 0.05 versus corresponding control
group values. PMN, polymorphonuclear cells; MPC, monocyte/macrophages.
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Analysis of several tissue parameters was complemen-
ted by quantification of blood and BAL total leukocyte
numbers. In wild type mice, bleomycin administration
caused marked leukocytosis at day 21, with a high
number of circulating PMN, PBMN and lymphocytes
(LY) being calculated (Additional file 1: Figure S1).
These profiles of circulating leukocyte subsets were
mildly affected by absence of AnxA1: a reduction in LY
Table 2 Densitometric analysis of LacZ gene expression in specific lung cells during the process of fibrosis induced by
bleomycin
Epithelial cells PMN Mono MPC
Intra-vascular Trans-migrated Intra-alveolar Intra-vascular Tissue Intra-alveolar
Sham 61 ± 3 53 ± 2 60 ± 2 65 ± 2 50 ± 3 55 ± 2 65 ± 3
Bleo 7d 108 ± 10 * 65 ± 3 103 ± 5 * 110 ± 6 * 63 ± 2 70 ± 3 * 73 ± 3
Bleo 21d 180 ± 20*** 60 ± 3 105 ± 4* 108 ± 5* 61 ± 2 105 ± 5 ** 111 ± 10 *
AnxA1 null mice were treated with bleomycin (0.15 U/Kg i.t.) at time 0 and lung collected at the reported time points. X-Gal staining was done as described in
Material and Methods. Values (densitometric units) are mean ± SEM of 10 histological tissue sections analyzed from five mice per group. * P < 0.05 versus sham
group values. ** P < 0.01 versus sham group values. *** P < 0.001 versus sham group values.
Figure 1 Analysis of endogenous AnxA1 protein and Anxa1 gene expression during lung fibrosis. (A-H;O-P) Wild type and (I-N) AnxA1
null mice received bleomycin i.t. at time 0. The AnxA1 protein content was analyzed by immunohistochemistry. At 0 time-point, wild type mice
exhibit a basal immunostain for AnxA1 protein (A and B). After 7 days post-bleomycin administration, this protein expression was greatly
increased (C and D). And, after 21 days, the AnxA1 expression was reduced (E and F) in epithelial cells (arrow) and polymorphonuclear (PMN)
(arrowheads) and MPC (curve arrow)(G and H). Control of immunogold reaction (CR) showing no cellular immunostaining. Anxa1 gene promoter
activity was visualized by X-Gal staining reaction. AnxA1 null mice lung showing Anxa1 gene expression (I and J) on the epithelial cells (arrow),
intravascular PMN (arrowhead) and MPC (curve arrow); an intense positive reaction was attained (K-N) on day 7 and 21 post-bleomycin
administration. Control for LacZ reaction (CR) showing wild type mice negative to the X-Gal staining (O and P). Haematoxylin counterstain. Bars,
10 μm.
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at day 7 as well as a less pronounced increase in PMN
could be measured at day 21 (Additional file 1: Figure
S1). In parallel analyses, a rapid cells influx of blood-
borne leukocyte into BAL fluid was detected, with
marked changes between wild type and AnxA1 null
mice especially for PMN (day 7 and day 21), PBMC
(day 21) and LY (day 7) (Additional file 1: Figure S1).
Histopathological and biochemical analysis of the lung
We then assessed the extent of pulmonary fibrosis in both
genotypes, using the Masson tri-chrome stain. Administra-
tion of saline to either wild type or AnxA1 null did not
lead to abnormal deposition of collagen around the
bronchiole, vessels or alveoli (Figure 3A and 3D). In con-
trast, at day 7 post-bleomycin, wild type mice showed no
significant increase in the connective tissue (Figure 3B),
with signs of severe fibrosis evident at day 21, with greater
destruction of alveolar architecture, more pronounced at
perivascular and peribronchial sites (Figure 3C). These
changes were also evident in AnxA1 null mice, both at 7
and 21 days post-bleomycin (Figures 3E and 3F).
Results obtained with the histopathological method were
confirmed by measuring hydroxyproline content in lung
tissue samples, to quantify the extent of collagen deposi-
tion. Both wild type and AnxA1 null bleomycin-treated
mice had significantly higher fibrosis scores than saline-
treated corresponding mice (Additional file 2: Figure S2).
Moreover, there was a statistically significant difference
(+23.5% at day 7; +20% at day 21) between wild type and
AnxA1 null bleomycin-treated mice, indicating induction
of a higher degree of pulmonary fibrosis in the latter geno-
type (Additional file 2: Figure S2).
Bleomycin-induced fibrosis is lethal in AnxA1 null mice
Why the observation is surprising to observe that a pro-
portion of AnxA1 null mice succumbed during the
time-course of these experiments, with a progressive
incidence of lethality from day 7: at day 21 ~50% of
bleomycin-treated mice had died (Figure 4). No lethality
was observed in wild type animals up to the day 21.
Cytokine levels in bleomycin-induced fibrosis
It is accepted that TGF-b1, IFN-g and TNF-a are key
cytokines in the fibrotic process of the lung initiated by
bleomycin [3,29]. Thus, we analyzed cytokine levels as a
possible cause behind the increased signs of fibrosis and
collagen accumulation detected in AnxA1 null mice.
Figure 3 Lung histopathology. (A-C) Wild type and (D-F) AnxA1
null mice lung were analyzed at 0, 7 and 21 days post-bleomycin i.
t. administration as described in Material and Methods section. (A
and D) Histological analysis of wild type and AnxA1 null mouse
lungs showing presence of collagen in the connective tissue in the
lung parenchyma (a), near the vessel (v) and bronchiole (b). (B) No
major changes in the connective tissue of wild type lung
parenchyma, as observed at day 7 post-bleomycin administration.
(C) At day 21 post-bleomycin, the alveolar septa thicken because of
a significant increase in connective tissue deposit (arrow). (E and F)
In the AnxA1 null mice, the fibrosis was evident already at day 7; by
day 21 there is evidence of increased connective tissue (arrows).
Masson trichrome stain. Bars, 100 μm.
Figure 2 Leukocyte influx into the lung tissue. Semiquantitative
analysis of the histological sections showing intravascular
polymorphonuclear (PMN) and monocytes (mono), and
transmigrated PMN and MPC in lung tissue. Wild type and AnxA1
null mice were analyzed at 0, 7 and 21 days post-bleomycin i.t.
administration as described in Methods section. Data are mean ±
SEM from 5 mice per time point. *P < 0.05 versus 0 time point wild
type group values; **P < 0.01 versus 0 time point wild type group
values; ***P < 0.001 versus 0 time point wild type group values; #P
< 0.05 versus corresponding wild type group values; ###P < 0.01
versus corresponding wild type group values.
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Figure 5 shows a marked time-dependent increase
(>15-fold) in circulating IFN-g upon bleomycin treat-
ment, whereas changes in TGF-b1 and TNF-a were
more modest (between 2-3 fold over untreated mice,
day 0 values). Furthermore, higher serum TGF-b1 and
TNF-a levels were measured at day 7 in AnxA1 null
mice. Similar changes were seen in BAL fluid samples,
with discrete alterations of these values in samples taken
from AnxA1 null mice (Figure 5). As an example, BAL
TNF-a was higher at day 7, with BAL IFN-g being
increased at day 21. TGF-b1 was mildly affected by the
absence of endogenous AnxA1.
Regulatory actions of peptide Ac2-26
Finally, we tested whether treatment of wild type mice
with an AnxA1 mimetic would affect the dramatic
Figure 5 Serum and BAL supernatant cytokine levels. Wild type and AnxA1 null mice received bleomycin i.t. at time 0, with blood and BAL
samples being collected at the reported time points. The serum and cell-free supernatant BAL concentration of TGF-b1, IFN-g and TNF-a was
determined by ELISA. Results are mean ± SEM from two separate experiments with 5 mice per group. *P < 0.05,**P < 0.01 and ***P < 0.001
versus 0 time point wild type group values; #P 0.05 versus corresponding wild type group values.
Figure 4 Bleomycin lethality in AnxA1 null mice. Wild type and
AnxA1 null mice received 0.15 U/Kg bleomycin i.t. at time 0 and
survival rate was monitored daily up to 21 days. Results are
cumulated from three experiments with a total of 15 mice per
group.
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changes provoked by bleomycin in the lung. Two proto-
cols were used for administration of this peptide.
Histological analyses showed that the peptide Ac2-26
treatment reduced the extracellular deposition of col-
lagen when compared to mice treated with bleomycin
alone (Figure 6B and 6C). In the group of mice treated
with peptide Ac2-26, daily from day 0, a clear reduction
in connective tissue deposition around the bronchiolar
epithelium was observed, with some similarity to the
morphological structure of the sham group (Figure 6A
and 6C). Similar protection of the lung was afforded
when the peptide was administered between days 14 to
21 post-bleomycin, as determined by quantification of
lung hydroxyproline content (Figure 6D). A control
group treated daily with peptide Ac2-26 i.p., and given
saline i.t., did not show significant morphological
changes in the lung tissue (data not shown).
Treatment of mice with peptide Ac2-26 led to an
increased expression of endogenous AnxA1 protein in
the lung (Figure 7E and 7F), when compared to bleomy-
cin treatment alone (Figure 7C and 7D). The changes
provoked by peptide Ac2-26 occurred in the alveolar
macrophage and the epithelial cell and the expressions
were higher than sham group (saline treated) (Figure
7E/F and 7A/B, respectively). Western blotting analyses
confirmed these histological results, showing augmented
AnxA1 in lung protein extracts prepared from mice
treated with peptide Ac2-26 over 21 days or only for the
Figure 6 Effects of treatment with peptide Ac2-26 on lung fibrosis and hydroxyproline content. Lung were analyzed at 0 and 21 days
post-bleomycin i.t. administration. Also a group of mice were daily treated i.p. with the peptide Ac2-26 (1 mg/kg) or between the days 14 to 21
post-bleomycin as described in Methods section. (A) Morphological analysis of sham group indicated the reduced content of collagen in the
lung parenchyma (a), near the vessels (v) and bronchiole (b). (B) At day 21 after bleomycin administration, the alveolar septa thickening indicated
the significantly increasement of collagen deposit (arrows). (C) The daily treatment with peptide Ac2-26 prevents bleomycin-induced lung fibrosis
(curve arrows). Masson trichrome stain. Bar, 100 μm. (D) Pulmonary fibrosis was biochemically assessed by measurement of lung hydroxyproline
content. Results are expressed as means ± SEM of μg of hydroxyproline per mg of lung tissue. **P < 0.01 versus 0 time point values; #P < 0.05
versus day 21 post-bleomycin time point values.
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Figure 7 Analysis of endogenous AnxA1 expression in wild type mice after treatment with peptide Ac2-26. Mice received bleomycin i.t.
at time 0. Immunohistochemistry was performed to visualize the protein expression in epithelial cells (arrows), PMN (arrowheads) and alveolar
macrophages (curved arrow). (A and B) Sham mice exhibit a basal immunostain for AnxA1 protein. (C and D) Lung fibrosis induced by
bleomycin reduced the AnxA1 expression in epithelial cells (arrow) and PMN (arrowheads). (E and F) Daily treatment with peptide Ac2-26 (1 mg/
kg) increased the AnxA1 expression during lung fibrosis. Haematoxylin counterstain. Bar, 10 μm. (G) The AnxA1 protein content was also
analyzed by Western blotting (seen as both the native 37 kDa and 33 kDa cleavage products). AnxA1 was down regulated during lung fibrosis.
Daily i.p. treatment with peptide Ac2-26, or given only between day 14 and day 21 post-bleomycin, increased expression of this endogenous
protein.
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14-21 day period, when compared to bleomycin-treated
control mice (Figure 7G). Table 1 reports quantitative
data associated with these analyses at single cell level.
Discussion
Pulmonary fibrosis has a complex etiology involving
interactions among multiple cell types and intricate
cytokine/chemokine networks. However, the precise role
of any one of these cytokines in vivo is hard to identify
in view of their pleiotropic biological activities. Studies
using animal models afford a well-defined means of
addressing this problem since provide the opportunity
to target each of these putative mediators using immu-
nological and genetic approaches.
In line with the human fibrosis, the mechanisms
underlying bleomycin-induced lung fibrosis are not fully
understood, although several studies have identified
expression of specific cytokines and mediators with
potential functional role(s) during this process. We pro-
pose here that investigation of the potential modulation
of effectors of endogenous anti-inflammation could pro-
vide novel clues to harness the host response during
lung fibrosis [30]. Such a novel approach - exploiting
the functions of homeostatic and tissue protective med-
iators - would possibly be more successful than blockade
of the actions of pro-inflammatory mediators since anti-
cytokine therapy has produced no improvement in lung
function and, rather, seemed to be associated with
harmful side effects [6]. Few studies in humans and ani-
mals have demonstrated down regulation of one endo-
genous effector of resolution, the protein AnxA1, during
the development of cystic fibrosis [24,25]; the present
study was intended to address, for the first time, the
potential relevance of AnxA1 in experimental fibrosis
using the recently generated AnxA1 null mouse [14,15].
Analysis of AnxA1 protein expression in the bleomy-
cin-induced fibrosis indicated increased expression in
bronchial epithelial cells and leukocytes during the
inflammatory phase (7 days) followed by a reduction
during the fibrotic phase (21 days), as compared to
sham animals: this event is in agreement with changes
reported in lung tissue and leukocytes [24,25] in experi-
mental settings modeling tissue fibrosis.
We could monitor Anxa1 gene promoter activity in
leukocytes and epithelial cells using the AnxA1 null
mouse colony [12] where a LacZ gene reporter assay is
inserted in frame. At day 21 post-bleomycin, the X-Gal
staining detected higher Anxa1 gene promoter activity
in leukocytes and epithelial cells compared to day 0
lung tissue samples. These data, together with the
AnxA1 protein expression, indicate that despite the
lower levels of AnxA1 detected in the cells, there is
ample Anxa1 gene promoter activity; we wish to postu-
late that reduction in AnxA1 protein may be associated
with a post-transcriptional mechanism(s) which could
perhaps lead to AnxA1 proteolysis or leakage (aberrant
secretion) from the cells. AnxA1 lacks a signal peptide
yet it is released from cells (e.g. activated PMN; see ref.
31). Several non-canonical secretory pathways have been
ascribed, possibly in a cell specific fashion, including
phosphorylation [32], proteolysis [24,33], granule/mem-
brane fusion [34] and microparticles release [35]. Future
studies will attempt to establish the ‘preferred’ mode of
AnxA1 secretion in activated lung cells, though it can-
not be excluded that alternative mechanisms might be
operating in diseased cells.
At day 21, we could also measure a higher degree of
fibrosis and collagen deposition in AnxA1 null animals,
as detected both morphologically and by hydroxyproline
measurement. Therefore, AnxA1 down-regulation might
be an important determinant during lung fibrosis devel-
opment, suggesting that manipulation of local pulmon-
ary concentration of AnxA1, perhaps by adenoviral
delivery (a route successfully applied to lung pathologies;
[36], might represent a novel way to afford lung tissue
protection.
AnxA1 has been implicated in many aspects of cell
physiology including regulation of cell growth [37] and
differentiation [38], signal transduction and arachidonic
acid release [39], as well as intracellular vesicle traffick-
ing [40]. Moreover, it promotes cell apoptosis and, pos-
sibly more relevant, phagocytosis of apoptotic cells and
subsequent tissue clearance [23] has also been ascribed
to this homeostatic mediator.
Croxtall et al. [37] showed that a lung fibroblast cell
line derived from the AnxA1 null mouse was refractory
to growth inhibition by dexamethasone, indicating that
intracellular AnxA1 (though it cannot be excluded also
an extracellular role here) can function as a negative
regulator of cell growth. In pathology, AnxA1 has been
implicated directly or indirectly in tumor cell growth
[41,42]. Our previous results also showed an abnormal
growth formation in the AnxA1 null mice skull, prob-
ably caused by increased extracellular matrix and a
delay in the bone mineralization [43]. Thus, we would
postulate that absence of AnxA1 may lead to higher cell
proliferation, increasing the extracellular matrix produc-
tion and fibrosis formation. Studies by Nusrat’s lab [44]
have identified AnxA1 as a major effector of tissue pro-
tection following epithelial damage, an effect requiring
externalization of the protein.
In our experimental conditions, absence of AnxA1
affected several indices of the response promoted by
bleomycin, characterized by an early inflammatory phase
followed by the fibrotic process. The combined effect of
AnxA1 absence and bleomycin-induced fibrosis
exceeded the sum of the effects of each factor alone on
the severity of histological changes. This was visible
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because the higher degree of activation of circulating
leukocyte and a remarkable leukocyte infiltration to the
alveolar space and lung parenchyma; these cellular
events led, or at least contribute, to: i) a more severe
inflammatory response and ii) a greater destruction of
alveolar architecture, pronounced in the perivascular
and peribronchial areas. This effect is in line with our
previous data in different experimental models of
inflammation, including acute peritonitis [13] and lipo-
polysaccharide-induced systemic inflammation [12].
Absence of AnxA1 is conducive to increased leukocyte
infiltration leading to a more severe inflammatory reac-
tion. Several studies have associated inflammatory cell
recruitment and lung damage with fibrosis formation
[7,45], prompting us to propose that alteration in the
early protective role of AnxA1 during the inflammatory
phase could lead, downstream, to a higher degree of
fibrosis.
So far we have two feasible mechanisms for explaining
the impact of AnxA1 in this model: i) direct alteration
in the phenotype of lung cells potentially, but not neces-
sarily, related to a ii) more aggressive inflammatory
reaction. Analysis of cytokine content favors a functional
association between these two readouts. In fact, tightly
coupled to the early inflammatory response is a higher
cytokine expression. We measured TNF-a, TGF-b1 and
IFN-g since they instrumental for the inflammatory pro-
cess and/or fibrosis [46,47]. In wild type mice, levels of
these cytokines changed in the blood and BAL fluid
samples. TGF-b1 is largely responsible for fibroblast
activation/differentiation, as well as collagen over-
expression [3]. Furthermore, a lower degree of parench-
ymal inflammation has been observed in IFN-g deficient
mice subjected to the bleomycin-induced lung fibrosis
model [45]. In our samples we could determine a corre-
lation between increased levels of TGF-b1 with TNF-a
and IFN-g up-regulation. Hardie and collaborators [48]
showed that TGF-b1 conditional over-expression in
epithelial cells, endothelial cells and macrophages
induces fibrosis and TNF-a expression even in the
absence of inflammation. It is plausible that complex
positive loops might be activated locally, since TGF-b1
induction from macrophages occurs in a two-stage pro-
cess requiring both TNF-a and IL-13 [49].
Global absence of AnxA1 resulted in dysregulated pul-
monary levels of TNF-a, TGF-b1 and IFN-g, more evi-
dent at day 21, yet present also at day 7 post-bleomycin.
This association of AnxA1 with TNF-a expression is
not totally unexpected as previously reported in a model
of systemic endotoxemia induced by LPS [12,50]. More
studies will better address the molecular events behind
AnxA1 regulation of cytokine production in lung cells.
Finally, we tested the potential pharmacological bene-
fit of treatment of mice with peptide Ac2-26. This
peptide mimics most [10,31,51], if not all [21], of the
pharmacological actions of AnxA1. Given daily over 21
days, or from day 14 to 21, peptide Ac2-26 reduced the
most remarkable feature of the animal response to bleo-
mycin, which is fibrosis, as quantified both histologically
and by determination of lung hydroxyproline content.
An interesting observation stemmed from these experi-
ments, that is the positive effect of treatment of mice with
peptide Ac2-26 on tissue levels of AnxA1, indicating that
a positive loop might exist in anti-inflammation, whereby
AnxA1 activation of its receptor (here the activation is
achieved by the AnxA1 pharmacophore peptide Ac2-26)
would augment its own synthesis, in epithelial cells and in
some leukocytes subsets (Table 1). Such a model is con-
gruent with a recent study in mouse colitis, which revealed
the ability of treatment with peptide Ac2-26 to increase
tissue mRNA for AnxA1 receptors [44]. The same held
true for epithelial cells treated with AnxA1 [52]. There-
fore, different studies are coming together with indications
for the existence of this positive loop; if extended to other
settings; this would indicate possible “auto-reactivity” of
endogenous anti-inflammation and resolution, at least
with respect to the AnxA1 pathway.
Conclusions
In summary, the striking phenotype we describe here
indicates that endogenous and exogenous AnxA1 affects
selective aspects of the process of fibrosis development
in the lung, a feature that may warrant further investiga-
tion on AnxA1 biology in these experimental and patho-
logical settings.
Additional material
Additional file 1: Figure 1S. Time course of leukocyte influx in the
blood and the bronco-alveolar lavage (BAL). Wild type and AnxA1
null mice received bleomycin i.t. at time 0. At different time points,
blood aliquots were collected for lymphocyte (LY), peripheral blood
monocyte (PBMN) and polymorphonuclear (PMN) quantification; BAL
were also performed for measuring LY, mononuclear phagocytic cells
(MPC) and PMN. Data are mean ± SEM from two separate experiments
with 5 mice each. *P < 0.05, **P < 0.01 and ***P < 0.001 versus 0 time
point wild type group values; #P < 0.05 and ###P < 0.01 versus
corresponding wild type group values.
Additional file 2: Figure 2S. Effects of Anxa1 gene deletion on lung
hydroxyproline content. Pulmonary fibrosis was biochemically assessed
by measurement of lung hydroxyproline content at 0, 7 and 21 days
post-bleomycin i.t. administration in the wild type and AnxA1 null mice
as described in Material and Methods section. The absence of AnxA1
significantly increased the hydroxyproline content induced by bleomycin.
Results were expressed as means ± SEM of μg of hydroxyproline per mg
of lung tissue. *P < 0.05 and **P < 0.01 versus 0 time point wild type
group values; #P < 0.05 versus corresponding wild type group values.
Abbreviations
AnxA1: annexin A1; BAL: bronchoalveolar lavage; Bleo: bleomycin; ECM:
extracellular matrix; IFN-γ: interferon-γ; LY: lymphocytes; MPC: mononuclear
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phagocytic cells; PBMC: peripheral blood monocytes; PBS: phosphate-
buffered saline; PMN: polymorphonuclear; TGF-β1: transforming growth
factor-β1; TNF-α: tumor necrosis factor-α.
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